Epigenomic markers of circulating cell-free DNA and treatment response in multiple myeloma
Multiple Myeloma (MM) is generally incurable and patients will eventually develop relapsed/refractory disease. Early relapse is associated with poor clinical outcomes and overall survival. There are currently no effective markers that can predict which patients will have early relapse.